Research progress of effect of estrogen and its receptors on cholesterol gallstone disease

doi:10.3969/j.issn.1674-8115.2021.10.020

Abstract

Abstract:

Gallstone disease is a common disorder of the digestive system. Cholesterol supersaturation in bile and gallbladder contraction dysfunction are important pathophysiological mechanisms of cholesterol gallstone formation. Estrogen and its receptors can affect cholesterol gallstone formation through regulating cholesterol and bile acid metabolism and gallbladder contraction. Classical nuclear receptors such as estrogen receptor α and estrogen receptorβ, as well as novel membrane receptors such as G protein-coupled receptor 30, play an important role in cholesterol gallstone formation. The design and synthesis of selective antagonists targeting estrogen receptors may be a potential strategy for the prevention and treatment of cholesterol gallstone disease. In this paper, the research progress of effect of estrogen and its receptors on cholesterol gallstone disease in recent years is reviewed.

Key words: cholesterol gallstone disease, estrogen, estrogen receptor (ER), cholesterol, bile acid

CLC Number:

R575.6⁺2

Qian ZHUANG, Zhi-xia DONG, Xin-jian WAN. Research progress of effect of estrogen and its receptors on cholesterol gallstone disease[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(10): 1394-1396.

TrendMD

References 35

1	European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones[J]. J Hepatol, 2016, 65(1): 146-181.
2	中华消化杂志编辑委员会, 中华医学会消化病学分会肝胆疾病协作组. 中国慢性胆囊炎、胆囊结石内科诊疗共识意见(2018年)[J]. 中华消化杂志, 2019, 39(2): 73-79.
3	Shabanzadeh DM, Sørensen LT, Jørgensen T. A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study[J]. Gastroenterology, 2016, 150(1): 156-167.e1.
4	Shabanzadeh DM, Sørensen LT, Jørgensen T. Determinants for gallstone formation: a new data cohort study and a systematic review with meta-analysis[J]. Scand J Gastroenterol, 2016, 51(10): 1239-1248.
5	王启晗, 张中文, 吴健, 等. 上海地区胆囊结石病的流行病学调查[J]. 外科理论与实践, 2018, 23(3): 252-257.
6	朱颖, 吴治宇, 马向明, 等. 开滦集团职工胆囊结石临床流行病学调查[J]. 临床肝胆病杂志, 2015, 31(10): 1621-1624.
7	Wang HH, Portincasa P, Liu M, et al. An update on the lithogenic mechanisms of cholecystokinin a receptor (CCKAR), an important gallstone gene for Lith13[J]. Genes, 2020, 11(12): 1438.
8	Sieron D, Czerny B, Sieron-Stoltny K, et al. The effect of chronic estrogen application on bile and gallstone composition in women with cholelithiasis[J]. Minerva Endocrinol, 2016, 41(1): 19-27.
9	Simonsen MH, Erichsen R, Frøslev T, et al. Postmenopausal estrogen therapy and risk of gallstone disease: a population-based case-control study[J]. Drug Saf, 2013, 36(12): 1189-1197.
10	Murphy E. Estrogen signaling and cardiovascular disease[J]. Circ Res, 2011, 109(6): 687-696.
11	Lagranha CJ, Silva TLA, Silva SCA, et al. Protective effects of estrogen against cardiovascular disease mediated via oxidative stress in the brain[J]. Life Sci, 2018, 192: 190-198.
12	Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism[J]. Adv Exp Med Biol, 2017, 1043: 227-256.
13	Handgraaf S, Philippe J. The role of sexual hormones on the enteroinsular axis[J]. Endocr Rev, 2019, 40(4): 1152-1162.
14	Mauvais-Jarvis F, Le May C, Tiano JP, et al. The role of estrogens in pancreatic islet physiopathology[J]. Adv Exp Med Biol, 2017, 1043: 385-399.
15	Farman HH, Gustafsson KL, Henning P, et al. Membrane estrogen receptor α is essential for estrogen signaling in the male skeleton[J]. J Endocrinol, 2018, 239(3): 303-312.
16	Morselli E, Santos RDS, Gao S, et al. Impact of estrogens and estrogen receptor-α in brain lipid metabolism[J]. Am J Physiol Endocrinol Metab, 2018, 315(1): E7-E14.
17	Jacenik D, Cygankiewicz AI, Fichna J, et al. Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome[J]. Mol Cell Endocrinol, 2018, 471: 89-96.
18	Hewitt SC, Korach KS. Estrogen receptors: new directions in the new millennium[J]. Endocr Rev, 2018, 39(5): 664-675.
19	Barton M, Filardo EJ, Lolait SJ, et al. Twenty years of the G protein-coupled estrogen receptor GPER: historical and personal perspectives[J]. J Steroid Biochem Mol Biol, 2018, 176: 4-15.
20	Rebholz C, Krawczyk M, Lammert F. Genetics of gallstone disease[J]. Eur J Clin Invest, 2018, 48(7): e12935.
21	蒋兆彦, 胡海, 韩天权, 等. 胆固醇的肠肝循环: 肝脏和小肠在胆石形成中的作用[J]. 外科理论与实践, 2017, 22(3): 191-194.
22	Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease[J]. Curr Opin Gastroenterol, 2018, 34(2): 71-80.
23	Cortés VA, Barrera F, Nervi F. Pathophysiological connections between gallstone disease, insulin resistance, and obesity[J]. Obes Rev, 2020, 21(4): e12983.
24	Lammert F, Gurusamy K, Ko CW, et al. Gallstones[J]. Nat Rev Dis Primers, 2016, 2: 16024.
25	Wang HH, Afdhal NH, Wang DQH. Estrogen receptor α, but not β, plays a major role in 17β-estradiol-induced murine cholesterol gallstones[J]. Gastroenterology, 2004, 127(1): 239-249.
26	Saha P, Shumate JL, Caldwell JG, et al. Inter-domain dynamics drive cholesterol transport by NPC1 and NPC1L1 proteins[J]. Elife, 2020, 9: e57089.
27	Duan LP, Wang HH, Ohashi A, et al. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects[J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290(2): G269-G276.
28	de Bari O, Wang HH, Portincasa P, et al. Ezetimibe prevents the formation of oestrogen-induced cholesterol gallstones in mice[J]. Eur J Clin Invest, 2014, 44(12): 1159-1168.
29	Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology[J]. Nat Rev Endocrinol, 2017, 13(12): 710-730.
30	Wang HH, Afdhal NH, Wang DQH. Overexpression of estrogen receptor α increases hepatic cholesterogenesis, leading to biliary hypersecretion in mice[J]. J Lipid Res, 2006, 47(4): 778-786.
31	de Bari O, Wang HH, Portincasa P, et al. The deletion of the estrogen receptor α gene reduces susceptibility to estrogen-induced cholesterol cholelithiasis in female mice[J]. Biochim Biophys Acta, 2015, 1852(10Pt A): 2161-2169.
32	de Bari O, Wang TY, Liu M, et al. Estrogen induces two distinct cholesterol crystallization pathways by activating ERα and GPR30 in female mice[J]. J Lipid Res, 2015, 56(9): 1691-1700.
33	Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30[J]. Nat Chem Biol, 2006, 2(4): 207-212.
34	Wang HH, de Bari O, Arnatt CK, et al. Activation of estrogen receptor G protein-coupled receptor 30 enhances cholesterol cholelithogenesis in female mice[J]. Hepatol, 2020, 72(6): 2077-2089.
35	DeLeon C, Wang HH, Gunn J, et al. A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice[J]. J Lipid Res, 2020, 61(5): 767-777.

[1]	Yue-ting JIANG, Jia-ying NI, Shen-rui GUO, Han LI, Yu-jia ZHUANG, Feng WANG. Physiological function of cholesterol sulfate and its role in related diseases [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(3): 371-375.
[2]	HE Qin, ZHANG Wei-bin, SHEN Yu-hui. Establishment of a prognostic scoring model for the breast cancer patients with spinal metastasis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(09): 1243-1248.
[3]	ZOU Chen1, 2, XU Run-hao1, 3, ZHANG Hong2, MA Zhan2, CHEN Li2, ZHANG Jie3, LI Min3, ZHANG Shu-lin1. Potential roles of small metabolites in the differential diagnosis between lung cancer and pneumonia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(08): 1041-1047.
[4]	LI Sen1, JIA Zi-heng1, WEI Xue-rui1, MA Sai1, LU Tian-cheng1, LI Ting-ting2, GU Yan-yun2. Role of bile acid on maintaining metabolic homeostasis [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(08): 1126-1130.
[5]	LIU Jiang-bo1, 2, WANG Li-hua1, ZUO Xiao-lei3. Research of live cell membranes modification based on cholesterol-DNA [J]. , 2019, 39(9): 969-.
[6]	JIA Yan1,2, WANG Hui-wen1, YI Jin-mou1, ZENG Hui2, LU Min3. Effect of the PI3K/AKT signaling pathway regulatedHMGCS1 on drug sensitivity of HL-60 cells [J]. , 2019, 39(9): 991-.
[7]	LU Yu-jie, JIN Ze-yu, LI Ya-fen, SHEN Kun-wei, CHEN Wei-guo, CHEN Xiao-song. Receptor status testing and its influence on following treatment selection in breast cancer patients with loco-regional recurrence [J]. , 2019, 39(9): 1071-.
[8]	ZHAO Ming-liang1, 2, ZHAO Ai-hua1, ZHENG Xiao-jiao1, JIA Wei1. Role of farnesol X receptor in glycolipid metabolism regulation [J]. , 2019, 39(6): 671-.
[9]	KUANG Jun-liang, ZHENG Xiao-jiao, ZHAO Ai-hua, JIA Wei. Alterations in bile acid levels in metabolic diseases and related treatment strategies [J]. , 2019, 39(6): 678-.
[10]	LI Hu-xiao, SONG Zhong-chen. Advance in phytoestrogenic effects of psoralen [J]. , 2019, 39(2): 203-.
[11]	ZHAO Jing-yu, HUANG Ming-jian, ZHANG Xiao-ling. Effects of estrogen on proliferation, apoptosis and differentiation of bone marrow macrophage [J]. , 2018, 38(7): 745-.
[12]	CHEN Xiao-mei1, CHEN Zi-jin2, MA Xiao-bo2, ZHANG Chun-li2, QIAN Ying2, YU Hai-jin2, CHEN Xiao-nong2. Progression of left ventricular hypertrophy in maintenance hemodialysis patients and analysis of risk factors [J]. , 2018, 38(5): 505-.
[13]	LUO Cong-cong1,BAO Chun-rong2,HE Bin1. Clinical advances in monoclonal antibody against PCSK9 for coronary atherosclerotic heart disease [J]. , 2018, 38(3): 339-.
[14]	XUE Yu-chen, YOU Sha-sha, CAO Hui-min, HE Bin. Vaccine strategies in prevention and treatment of atherosclerosis#br# [J]. , 2018, 38(1): 108-.
[15]	FENG Sui-bin, LIU Hai-jun, ZHOU Zhou, WANG Xiao, HU Cheng, ZHANG Xue-li1. Effect of Roux-en-Y gastric bypass surgery on hepatic glucolipid metabolism in rats with obesity combined with type 2 diabetes mellitus#br# [J]. , 2017, 37(9): 1201-.